Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 31 Aug 2023

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches

in Cancer Molecular Targets and Therapeutics

Marjolein Verhoeven
Eline A. M. Ruigrok
Geert J. L. H. van Leenders
Lilian van den Brink
Hayri E. Balcioglu
Wytske M. van Weerden
Simone U. Dalm

Frontiers in Oncology

doi 10.3389/fonc.2023.1199432

3,917 views
10 citations

Original Research

Published on 31 Aug 2023

Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations

in Cancer Molecular Targets and Therapeutics

Benedikt Färber
Olga Lapshyna
Axel Künstner
Michael Kohl
Thorben Sauer
Kira Bichmann
Benjamin Heckelmann
Jessica Watzelt
Kim Honselmann
Louisa Bolm

Frontiers in Oncology

doi 10.3389/fonc.2023.1230382

3,098 views
2 citations

Original Research

Published on 31 Aug 2023

MiR-4270 acts as a tumor suppressor by directly targeting Bcl-xL in human osteosarcoma cells

in Cancer Molecular Targets and Therapeutics

Clément Veys
Flavie Boulouard
Abderrahim Benmoussa
Manon Jammes
Emilie Brotin
Françoise Rédini
Laurent Poulain
Nicolas Gruchy
Christophe Denoyelle
Florence Legendre

Frontiers in Oncology

doi 10.3389/fonc.2023.1220459

1,637 views
2 citations

Original Research

Published on 30 Aug 2023

miRNome expression analysis in canine diffuse large B-cell lymphoma

in Cancer Molecular Targets and Therapeutics

Nelly O. Elshafie
Michael Gribskov
Nathanael I. Lichti
Ekramy. E. Sayedahmed
Michael O. Childress
Andrea P. dos Santos

Frontiers in Oncology

doi 10.3389/fonc.2023.1238613

2,674 views
5 citations

Original Research

Published on 21 Aug 2023

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

in Cancer Molecular Targets and Therapeutics

Chian-Wei Chen
Chien-Yu Lin
Jeng-Shiuan Tsai
Chia-Yin Lin
Chao-Chun Chang
Yi-Ting Yen
Yau-Lin Tseng
Po-Lan Su
Chien-Chung Lin

Frontiers in Oncology

doi 10.3389/fonc.2023.1238876

2,128 views
1 citation

Mini Review

Published on 17 Aug 2023

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment

in Cancer Molecular Targets and Therapeutics

Hoda Pourhassan
Vaibhav Agrawal
Vinod Pullarkat
Ibrahim Aldoss

Frontiers in Oncology

doi 10.3389/fonc.2023.1237031

9,772 views
12 citations

Original Research

Published on 17 Aug 2023

Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells

in Cancer Molecular Targets and Therapeutics

Elnaz Salmani-Javan
Davoud Jafari-Gharabaghlou
Esat Bonabi
Nosratollah Zarghami

Frontiers in Oncology

doi 10.3389/fonc.2023.1193708

2,554 views
13 citations

Original Research

Published on 17 Aug 2023

Clinical outcomes after vascular reconstruction using synthetic grafts for limb salvage in patients with lower extremity sarcoma: a single-center retrospective experience

in Cancer Molecular Targets and Therapeutics

Chuanxi Zheng
Gang Xu
Wei Li
Xin Weng
Hongwei Yang
Zuhui Wang
Shiquan Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1199556

1,081 views

Systematic Review

Published on 16 Aug 2023

Clinicopathological and prognostic value of epithelial cell adhesion molecule in solid tumours: a meta-analysis

in Cancer Molecular Targets and Therapeutics

Peiwen Ding
Panyu Chen
Jiqi Ouyang
Qiang Li
Shijie Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1242231

1,862 views
2 citations

Original Research

Published on 15 Aug 2023

Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context

in Cancer Molecular Targets and Therapeutics

Justyna Czapla
Alina Drzyzga
Sybilla Matuszczak
Tomasz Cichoń
Marek Rusin
Magdalena Jarosz-Biej
Ewelina Pilny
Ryszard Smolarczyk

Frontiers in Oncology

doi 10.3389/fonc.2023.1249524

3,069 views
7 citations

Original Research

Published on 11 Aug 2023

Natural history of intraosseous low-grade chondroid lesions of the proximal humerus

in Cancer Molecular Targets and Therapeutics

Christopher M. LaPrade
Logan M. Andryk
Joshua L. Christensen
John C. Neilson
Adam N. Wooldridge
Donald A. Hackbarth
Manpreet Bedi
David M. King

Frontiers in Oncology

doi 10.3389/fonc.2023.1200286

4,355 views
4 citations

Case Report

Published on 11 Aug 2023

Case Report: Response to ALK-TKIs in a metastatic lung cancer patient with morphological heterogeneity and consistent molecular features

in Cancer Molecular Targets and Therapeutics

Yu Yang
Han Liu
Tao-hua Liu
Xi-run Zheng
Bin Wu
Dong-jing Zhou
Guang-juan Zheng
Xiao-shu Chai

Frontiers in Oncology

doi 10.3389/fonc.2023.1209799

1,835 views
1 citation

Review

Published on 08 Aug 2023

Hypoxia-induced cancer cell reprogramming: a review on how cancer stem cells arise

in Cancer Molecular Targets and Therapeutics

Genevieve M. Abd
Madison C. Laird
Jennifer C. Ku
Yong Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1227884

4,548 views
14 citations

Review

Published on 03 Aug 2023

Novel insights into biomarkers of progression in Desmoid tumor

in Cancer Molecular Targets and Therapeutics

Baiqi Liu
Zefang Sun
Rui Zhou
Dingcheng Shen
Shuai Zhu
Lu Chen
Gengwen Huang

Frontiers in Oncology

doi 10.3389/fonc.2023.1206800

2,309 views
2 citations

Review

Published on 03 Aug 2023

The integrated stress response in cancer progression: a force for plasticity and resistance

in Cancer Molecular Targets and Therapeutics

Caleb L. Lines
Morgan J. McGrath
Tanis Dorwart
Crystal S. Conn

Frontiers in Oncology

doi 10.3389/fonc.2023.1206561

9,487 views
26 citations

Original Research

Published on 01 Aug 2023

AI-powered discovery of a novel p53-Y220C reactivator

in Cancer Molecular Targets and Therapeutics

Shan Zhou
Dafei Chai
Xu Wang
Praveen Neeli
Xinfang Yu
Aram Davtyan
Ken Young
Yong Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1229696

10,121 views
7 citations